Absence of the BRAF mutation in HBME1+ and CK19+ atypical cell clusters in Hashimoto thyroiditis: Supportive evidence against preneoplastic change

American Journal of Clinical Pathology

Volumn 132, Issue 6, 2009, Pages 906-912

  Nasr, Michel R ^a   Mukhopadhyay, Sanjay ^a   Zhang, Shengle ^a   Katzenstein, Anna Luise A ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

BRAF mutation; Cytokeratin 19; Hashimoto thyroiditis; HBME1

Indexed keywords

ANTIBODY; B RAF KINASE; CYTOKERATIN 19; HBME1 ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; COLORIMETRY; DISEASE ASSOCIATION; GENE MUTATION; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STAINING; THYROID PAPILLARY CARCINOMA;

ADENOCARCINOMA, PAPILLARY; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HASHIMOTO DISEASE; HUMANS; KERATIN-19; MUTATION; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 72949121913     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPCGCZZ1OYF0IC     Document Type: Article

References (27)

1. Singh B, Shaha AR, Trivedi H, et al. Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery. 1999;126:1070-1076.
2. Berho M, Suster S. Clear nuclear changes in Hashimoto's thyroiditis: a clinicopathologic study of 12 cases. Ann Clin Lab Sci. 1995;25:513-521.
3. Gasbarri A, Sciacchitano S, Marasco A, et al. Detection and molecular characterisation of thyroid cancer precursor lesions in a specific subset of Hashimoto's thyroiditis. Br J Cancer. 2004;91:1096-1104.
4. Prasad ML, Huang Y, Pellegata NS, et al. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC. Histopathology. 2004;45:39-46.
5. Arif S, Blanes A, Diaz-Cano SJ. Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma. Histopathology. 2002;41:357-362.
6. Sheils OM, O'Leary JJ, Uhlmann V, et al. ret/PTC-1 activation in Hashimoto thyroiditis. Int J Surg Pathol. 2000;8:185-189.
7. Wirtschafter A, Schmidt R, Rosen D, et al. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope. 1997;107:95-100.
8. Nikiforova MN, Caudill CM, Biddinger P, et al. Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int J Surg Pathol. 2002;10:15-22.
9. Hunt JL, Baloch ZW, Barnes L, et al. Loss of heterozygosity mutations of tumor suppressor genes in cytologically atypical areas in chronic lymphocytic thyroiditis. Endocr Pathol. 2002;13:321-330.
10. Nasr MR, Mukhopadhyay S, Zhang S, et al. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining. Mod Pathol. 2006;19:1631-1637.
11. Prasad ML, Pellegata NS, Huang Y, et al. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol. 2005;18:48-57.
12. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245-262.
13. Jin L, Sebo TJ, Nakamura N, et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol. 2006;15:136-143.
14. Di Pasquale M, Rothstein JL, Palazzo JP. Pathologic features of Hashimoto's-associated papillary thyroid carcinomas. Hum Pathol. 2001;32:24-30.
15. Rhoden KJ, Unger K, Salvatore G, et al. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J Clin Endocrinol Metab. 2006;91:2414-2423.
16. Nikiforov YE. RET/PTC rearrangement: a link between Hashimoto's thyroiditis and thyroid cancer...or not. J Clin Endocrinol Metab. 2006;91:2040-2042.
17. Ishizaka Y, Kobayashi S, Ushijima T, et al. Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene. 1991;6:1667-1672.
18. Cinti R, Yin L, Ilc K, et al. RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH. Cytogenet Cell Genet. 2000;88:56-61.
19. Elisei R, Romei C, Vorontsova T, et al. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J Clin Endocrinol Metab. 2001;86:3211-3216.
20. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer. 2007;110:38-46.
21. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399-5404.
22. Sargent R, LiVolsi V, Murphy J, et al. BRAF mutation is unusual in chronic lymphocytic thyroiditis-associated papillary thyroid carcinomas and absent in non-neoplastic nuclear atypia of thyroiditis. Endocr Pathol. 2006;17:235-241.
23. Kim KH, Suh KS, Kang DW, et al. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis. Pathol Int. 2005;55:540-545.
24. van Hoeven KH, Kovatich AJ, Miettinen M. Immunocytochemical evaluation of HBME-1, CA 19-9, and CD-15 (Leu-M1) in fine-needle aspirates of thyroid nodules. Diagn Cytopathol. 1998;18:93-97.
25. Sack MJ, Astengo-Osuna C, Lin BT, et al. HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol. 1997;10:668-674.
26. Nasser SM, Pitman MB, Pilch BZ, et al. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining. Cancer. 2000;90:307-311.
27. Khurana KK, Truong LD, LiVolsi VA, et al. Cytokeratin 19 immunolocalization in cell block preparation of thyroid aspirates: an adjunct to fine-needle aspiration diagnosis of papillary thyroid carcinoma. Arch Pathol Lab Med. 2003;127:579-583.